SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-16-564211
Filing Date
2016-04-28
Accepted
2016-04-28 17:16:40
Documents
13
Period of Report
2016-06-14
Effectiveness Date
2016-04-28

Document Format Files

Seq Description Document Type Size
1 DEF 14A d153309ddef14a.htm DEF 14A 505706
2 GRAPHIC g153309g40b71.jpg GRAPHIC 6303
3 GRAPHIC g153309g57t15.jpg GRAPHIC 27674
4 GRAPHIC g153309g76r70.jpg GRAPHIC 90893
5 GRAPHIC g153309g88b19.jpg GRAPHIC 10691
6 GRAPHIC g153309g97d67.jpg GRAPHIC 55929
7 GRAPHIC g153309pc01a.jpg GRAPHIC 5861
8 GRAPHIC g153309pc01bnew.jpg GRAPHIC 30837
9 GRAPHIC g153309pc01cnew.jpg GRAPHIC 42071
10 GRAPHIC g153309pc01d.jpg GRAPHIC 8142
11 GRAPHIC g153309pc01e.jpg GRAPHIC 19975
12 GRAPHIC g153309pc01f.jpg GRAPHIC 44524
13 GRAPHIC g153309pc02.jpg GRAPHIC 5818
  Complete submission text file 0001193125-16-564211.txt   987666
Mailing Address 430 EAST 29TH STREET NEW YORK NY 10016
Business Address 430 EAST 29TH STREET NEW YORK NY 10016 212-923-3344
Intra-Cellular Therapies, Inc. (Filer) CIK: 0001567514 (see all company filings)

IRS No.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36274 | Film No.: 161601129
SIC: 2834 Pharmaceutical Preparations